Skip to main content

Avantor Inc (AVTR)

Drugs Health Care
Stock AI

Financial Metrics

Price to Earnings-16.3x
Revenue Growth (1Y)-1.57%
Debt to Equity0.66x

Strengths

Stock Chart

Valuation

Avantor Inc is undervalued

News

All
Press Releases
News
Filings
 Avantor® Reports Second Quarter 2026 Results
July 29, 2026 Avantor® Reports Second Quarter 2026 Results
10-Q Quarterly Report for 2026 Q2
July 29, 202610-Q Quarterly Report for 2026 Q2
 Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
July 14, 2026 Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
 Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
July 01, 2026 Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
 Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
May 19, 2026 Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
 Avantor® Reports First Quarter 2026 Results
April 29, 2026 Avantor® Reports First Quarter 2026 Results
10-Q Quarterly Report for 2026 Q1
April 29, 202610-Q Quarterly Report for 2026 Q1
 Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
April 23, 2026 Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
 Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
April 21, 2026 Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
 Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
April 13, 2026 Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
 Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
April 03, 2026 Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
 Avantor® Announces CFO Transition
April 01, 2026 Avantor® Announces CFO Transition
EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks
March 25, 2026EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks
Looking For A Rebound? China Tech and Emerging Markets Top Oversold List
March 04, 2026Looking For A Rebound? China Tech and Emerging Markets Top Oversold List
Software Slump Resumes, Bitcoin Plunges To $66,000: What's Moving Markets Wednesday?
February 11, 2026Software Slump Resumes, Bitcoin Plunges To $66,000: What's Moving Markets Wednesday?
Avantor Falls To Critical Levels As CEO Signals Investment Year Amid Soft Guidance
February 11, 2026Avantor Falls To Critical Levels As CEO Signals Investment Year Amid Soft Guidance
 Avantor® Reports Fourth Quarter and Full Year 2025 Results
February 11, 2026 Avantor® Reports Fourth Quarter and Full Year 2025 Results
10-K Annual Report for 2025 FY
February 11, 202610-K Annual Report for 2025 FY
 Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026
January 12, 2026 Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026
 Avantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026 Avantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Avantor Investors Have Opportunity to Lead Class Action Lawsuit
December 29, 2025FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Avantor Investors Have Opportunity to Lead Class Action Lawsuit
Deadline Soon: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
December 26, 2025Deadline Soon: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Avantor
December 21, 2025SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Avantor
 Avantor® Appoints Simon Dingemans to its Board of Directors
December 18, 2025 Avantor® Appoints Simon Dingemans to its Board of Directors
 Avantor® Appoints Sanjeev Mehra to its Board of Directors
December 04, 2025 Avantor® Appoints Sanjeev Mehra to its Board of Directors
AVTR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Avantor, Inc. Investors
December 03, 2025AVTR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Avantor, Inc. Investors
Labaton Keller Sucharow LLP Files Securities Class Action Against Avantor, Inc. and Certain of Its Executives
November 25, 2025Labaton Keller Sucharow LLP Files Securities Class Action Against Avantor, Inc. and Certain of Its Executives
 Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology
November 25, 2025 Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology
 Avantor® Expands Centralized Service Center Model with Opening of Boston-Area Facility
November 19, 2025 Avantor® Expands Centralized Service Center Model with Opening of Boston-Area Facility
Stock Market Today: Dow Jones, S&P 500 Futures Tumble—Home Depot, Axalta Coating Systems, Molina Healthcare In Focus
November 18, 2025Stock Market Today: Dow Jones, S&P 500 Futures Tumble—Home Depot, Axalta Coating Systems, Molina Healthcare In Focus
Deadline Alert: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
November 10, 2025Deadline Alert: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
 Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer
November 10, 2025 Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer
Deadline Approaching: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith
November 07, 2025Deadline Approaching: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action
November 06, 2025Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Avantor
November 06, 2025SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Avantor
Law Offices of Frank R. Cruz Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action
November 05, 2025Law Offices of Frank R. Cruz Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action
November 05, 2025Law Offices of Howard G. Smith Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action
Securities Fraud Investigation Into Avantor, Inc. (AVTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
November 03, 2025Securities Fraud Investigation Into Avantor, Inc. (AVTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Avantor Struggles With Soft Demand But Backs Long-Term Value Through Buyback
October 29, 2025Avantor Struggles With Soft Demand But Backs Long-Term Value Through Buyback
10-Q Quarterly Report for 2025 Q3
October 29, 202510-Q Quarterly Report for 2025 Q3
Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts
August 11, 2025Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts
Activist Investor to Push Avantor to Make Changes or Sell Itself
August 11, 2025Activist Investor to Push Avantor to Make Changes or Sell Itself
Activist Investor to Push Avantor to Make Changes or Sell Itself
August 10, 2025Activist Investor to Push Avantor to Make Changes or Sell Itself
Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure
August 01, 2025Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure
10-Q Quarterly Report for 2025 Q2
August 01, 202510-Q Quarterly Report for 2025 Q2
GREGORY SUMME Takes a Bullish Stance: Acquires $375K In Avantor Stock
May 28, 2025GREGORY SUMME Takes a Bullish Stance: Acquires $375K In Avantor Stock
Avantor Board Member Makes $253K Stock Purchase
May 23, 2025Avantor Board Member Makes $253K Stock Purchase
Eye On Growth: Jonathan Peacock Adds $103K Of Avantor Stock To Portfolio
April 30, 2025Eye On Growth: Jonathan Peacock Adds $103K Of Avantor Stock To Portfolio
Goldman Sachs Downgrades Avantor As Shares Spiral 60% Since 2021: 'We Wrongly Assumed...'
April 29, 2025Goldman Sachs Downgrades Avantor As Shares Spiral 60% Since 2021: 'We Wrongly Assumed...'
Avantor Analysts Cut Their Forecasts After Q1 Results
April 28, 2025Avantor Analysts Cut Their Forecasts After Q1 Results
Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift
April 25, 2025Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift
10-Q Quarterly Report for 2025 Q1
April 25, 202510-Q Quarterly Report for 2025 Q1
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
February 20, 2025Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?
February 09, 2025Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?
Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?
February 07, 2025Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?
Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025
February 07, 2025Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025
10-K Annual Report for 2024 FY
February 07, 202510-K Annual Report for 2024 FY
10-Q Quarterly Report for 2024 Q3
October 25, 202410-Q Quarterly Report for 2024 Q3
10-Q Quarterly Report for 2024 Q2
July 26, 202410-Q Quarterly Report for 2024 Q2
10-Q Quarterly Report for 2024 Q1
April 26, 202410-Q Quarterly Report for 2024 Q1
10-K Annual Report for 2023 FY
February 14, 202410-K Annual Report for 2023 FY
10-Q Quarterly Report for 2023 Q3
October 27, 202310-Q Quarterly Report for 2023 Q3
10-Q Quarterly Report for 2023 Q2
July 28, 202310-Q Quarterly Report for 2023 Q2
10-Q Quarterly Report for 2023 Q1
April 28, 202310-Q Quarterly Report for 2023 Q1
10-K Annual Report for 2022 FY
February 14, 202310-K Annual Report for 2022 FY
10-Q Quarterly Report for 2022 Q3
October 28, 202210-Q Quarterly Report for 2022 Q3
10-Q Quarterly Report for 2022 Q2
July 29, 202210-Q Quarterly Report for 2022 Q2
10-Q Quarterly Report for 2022 Q1
April 29, 202210-Q Quarterly Report for 2022 Q1
10-K Annual Report for 2021 FY
February 11, 202210-K Annual Report for 2021 FY
10-Q Quarterly Report for 2021 Q3
October 29, 202110-Q Quarterly Report for 2021 Q3

A. Company Overview

Avantor, Inc. is recognized as a prominent global provider of essential products and services that support research and operational needs within key sectors such as biopharma, healthcare, education, government, and advanced technologies and applied materials. Established in 1904 with the founding of the J.T. Baker Chemical Company, Avantor has its roots deeply embedded in the scientific community and has evolved through significant expansions and mergers. The company was incorporated in Delaware in May 2017 in anticipation of its acquisition of VWR, and it became publicly traded on the New York Stock Exchange in May 2019.

Avantor operates with a clear mission: to advance science and create solutions that contribute to a better world. This commitment manifests in the company’s support for customers from the initial stages of research through to large-scale manufacturing, ensuring a reliable supply of mission-critical products and services.

B. Business Segments

Avantor divides its operations into geographic segments, specifically: the Americas, Europe, and AMEA (Africa, Middle East, Asia). In late 2023, it was announced that the company would transition to two primary business segments effective January 1, 2024. These segments will focus on Lab Solutions and Bioscience Production.

The two new business segments reflect a consolidated approach to meeting customer needs and streamline operations across the various fields in which the company is involved. The three original geographic segments allowed Avantor to capture market dynamics and customer demands tailored to their specific regions.

C. Products and Services

Avantor's extensive product and service portfolio caters to diverse scientific and industrial requirements. This includes:

  • Materials & Consumables: This category encompasses ultra-high purity chemicals, lab supplies, formulated silicone materials, customized excipients, and various research and clinical trial kits among others. Significant portions of Avantor’s offerings are proprietary, ensuring high standards for quality and purity.
  • Equipment & Instrumentation: Avantor provides a range of advanced equipment including filtration systems, analytical instruments, and biological safety cabinets, all tailored to meet regulatory standards pertinent to the industries served.
  • Services & Specialty Procurement: The company offers an array of specialized services that enhance laboratory operations, including logistical support, procurement, and tailored scale-up services for biopharmaceutical materials.

These products and services form the backbone of Avantor's business model, with over 85% of net sales derived from recurring product offerings.

D. Customers

Avantor boasts a diversified customer base comprising over 300,000 client locations in more than 180 countries. Approximately 40% of the company’s net sales in 2023 were generated from long-standing customers with which it has maintained relationships for over 15 years. This deep-rooted customer loyalty is indicative of Avantor's commitment to quality service and products.

The company's approach to customer relationship management aims to ensure a nuanced understanding of customer needs while providing the necessary support and innovation to meet evolving market demands.

E. Suppliers

The supplier network of Avantor consists of both proprietary products developed in-house and third-party products sourced from a wide range of global suppliers. The company fosters long-term relationships with many suppliers, some of which span more than two decades. These partnerships often include contracts that may involve exclusivity provisions or collaboration on product development, thereby enhancing the value offering provided to customers.

F. Sales Channels

Avantor utilizes a multifaceted sales strategy that includes direct sales through a trained global sales force, e-commerce platforms, and targeted catalogs. A notable feature of Avantor's operations is its digital e-commerce platform, Avantor ScienceCentral, which streamlines the purchasing process and integrates analytics to enhance customer experience.

In 2023, approximately 75% of all transactions occurred digitally, demonstrating a strong inclination towards adopting technology within the sales framework. This e-commerce approach has improved access to products and services while offering bespoke solutions to customer challenges.

G. Infrastructure

Avantor maintains a vast operational infrastructure with over 200 facilities worldwide, including 45 manufacturing plants that comply with current good manufacturing practices (cGMP). The company’s facilities are strategically located to leverage supply chain efficiencies while ensuring timely delivery and compliance with regulatory standards across various regions.

The firm also operates numerous innovation centers aimed at fostering collaboration with clients and customizing solutions for complex requirements. The laboratories and manufacturing facilities are equipped with cutting-edge technologies that support a flexible manufacturing environment capable of adapting to different production scales.

H. Information Technology

The company employs a sophisticated suite of Enterprise Resource Planning (ERP) systems that support standardized operations while offering insight into business processes. The global web infrastructure enables seamless integration with customers and suppliers, allowing rapid adaptability to new technological requirements and challenges.

I. Competition

Avantor operates in a highly competitive and fragmented market landscape that includes a range of regional and global providers. The competitive advantages of Avantor rest on its comprehensive product line, customization capabilities, exceptional service delivery, and a robust online shopping experience that supports customer needs.

The ability to adapt to customer demands and regulatory environments is crucial in maintaining a competitive edge in the life sciences sector. Avantor’s focus on product quality, customer intimacy, and broad market access position it favorably against competitors in the industry.

Stock Infos

SectorHealth Care
IndustryDrugs
CEOMichael Stubblefield

Dividends

Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.